Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Induction in Pediatric Lung Transplantation
NCT02266888Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2015
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lung transplant rejection comparing Rituximab Induction with Placebo Induction (2 arms). Primary endpoint: Time to Chronic Allograft Dysfunction, Retransplant, or Death at 35 months. Started Jan 2015; status: completed.
02
Drugs
rituximab
03
Conditions
lung transplant rejection
Beyond the preview
Go deeper on NCT02266888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02266888.